Skip to main content
Clinical Trials/NCT04357847
NCT04357847
Unknown
Not Applicable

Assessment of Endothelial and Haemostatic Changes During Severe SARS-CoV-2 Infection

University Hospital, Rouen1 site in 1 country100 target enrollmentApril 9, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Covid-19
Sponsor
University Hospital, Rouen
Enrollment
100
Locations
1
Primary Endpoint
Association of InterCellular Adhesion Molecule-1 plasma level with 28 days mortality
Last Updated
5 years ago

Overview

Brief Summary

The outbreak at covid-19 is caused by the SARS-CoV-2 virus. This virus can be responsible for severe respiratory failure but also for extra-respiratory organ dysfunctions associated with severe inflammatory stress. The endothelium is an important structure of the blood vessels and is implicated in the organ failure of many patients admitted in intensive care units. It could be affected by the virus and its alteration may explain the organ dysfunction of covid-19 ICU patients as well as the thrombotic processes frequently obstructed in this infection.

Registry
clinicaltrials.gov
Start Date
April 9, 2020
End Date
August 31, 2021
Last Updated
5 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
University Hospital, Rouen
Responsible Party
Principal Investigator
Principal Investigator

EBESNIER

Principal investigator

University Hospital, Rouen

Eligibility Criteria

Inclusion Criteria

  • all adult patients admitted in ICU for covid-19 disease within the past 24 hrs

Exclusion Criteria

  • bactrial co-infection at admission
  • expected death within the next 24 hrs
  • pregnancy

Outcomes

Primary Outcomes

Association of InterCellular Adhesion Molecule-1 plasma level with 28 days mortality

Time Frame: 24 hours

Plasma of covid-19 patients will be tested for endothelial injuries, notably with the measurement of InterCellular Adhesion Molecule 1 level by Enzym-Linked Immunosorbent Assay. The association of these levels with 28-days mortality will be evaluated as prognosis markers.

Secondary Outcomes

  • Association of Vascular Endothelial Growth Factor A plasma level with 28 days mortality(24 hours)
  • Association of von Willebrandt Factor with thrombotic events(24 hours)
  • Association of Viscoelastic testing with thrombotic events(24 hours)
  • Association of D-dimers plasma levels with thrombotic events(24 hours)
  • Association of soluble Vascular Endothelial Growth Factor Receptor type 1 with 28 days mortality(24 hours)
  • Association of syndecan -1 plasma level with 28 days mortality(24 hours)
  • Association of Endothelin-1 plasma level with 28 days mortality(24 hours)

Study Sites (1)

Loading locations...

Similar Trials